source
- Moderna sticks to 10% revenue growth goal despite Phase 3 norovirus vaccine missModerna said it will continue to aim for up to 10% revenue growth this year, even though its experimental norovirus vaccine did not achieve statistical significance in a Phase 3 interim analysis.…
- Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trialNovo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study. The trial enrolled…